Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer

John Merriman, Susan M. Sereika, Yvette P. Conley, Theresa A. Koleck, Yehui Zhu, Mary L. Phillips, Michele A. Bertocci, Adam M. Brufsky, Catherine M. Bender

Research output: Contribution to journalArticle

Abstract

Purpose: Women with breast cancer report varying frequencies of cognitive problems during adjuvant systemic therapy. This variability suggests latent subgroups. Therefore, we identified latent subgroups of self-reported cognitive problems among postmenopausal women with and without breast cancer. We explored associations between membership in these subgroups and (a) demographic, clinical, and symptom characteristics and (b) variations in candidate gene polymorphisms. Methods: We evaluated frequency of cognitive problems using the Patient Assessment of Own Functioning Inventory. Growth mixture modeling identified latent subgroups over 18 months of adjuvant systemic therapy and at matched time points for women without cancer (N = 331). We evaluated for differences among subgroups in demographic, clinical, and symptom characteristics and in 41 single nucleotide polymorphisms in 10 candidate genes involved in DNA repair and oxidative stress pathways (n = 199). We modeled associations between genotypes and subgroup membership using multinomial logistic regression. Results: We identified three latent subgroups: more frequent, persistent, and almost never. Receipt of chemotherapy plus anastrozole, depressive symptoms, and baseline neuropathic symptoms increased the odds of belonging to the more frequent subgroup. Anxiety and depressive symptoms increased the odds of belonging to the persistent subgroup. With covariates controlled for, carrying the ERCC5 rs873601 G minor allele increased the odds of reporting more frequent cognitive problems. Conclusions: Chemotherapy plus anastrozole, depressive symptoms, and presence of neuropathic symptoms may predict more frequent cognitive problems during systemic therapy that later resolve. Mood dysregulation before therapy may predict persistent cognitive problems during therapy. ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors.

Original languageEnglish (US)
Pages (from-to)50-60
Number of pages11
JournalBiological Research for Nursing
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

DNA Repair
Oxidative Stress
Breast Neoplasms
Genes
Depression
Genotype
Demography
Therapeutics
Drug Therapy
Single Nucleotide Polymorphism
Anxiety
Logistic Models
Alleles
Equipment and Supplies
Growth
Neoplasms
anastrozole

Keywords

  • breast neoplasms
  • cognition
  • DNA repair
  • oxidative stress
  • self-report

ASJC Scopus subject areas

  • Research and Theory

Cite this

Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. / Merriman, John; Sereika, Susan M.; Conley, Yvette P.; Koleck, Theresa A.; Zhu, Yehui; Phillips, Mary L.; Bertocci, Michele A.; Brufsky, Adam M.; Bender, Catherine M.

In: Biological Research for Nursing, Vol. 21, No. 1, 01.01.2019, p. 50-60.

Research output: Contribution to journalArticle

Merriman, John ; Sereika, Susan M. ; Conley, Yvette P. ; Koleck, Theresa A. ; Zhu, Yehui ; Phillips, Mary L. ; Bertocci, Michele A. ; Brufsky, Adam M. ; Bender, Catherine M. / Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. In: Biological Research for Nursing. 2019 ; Vol. 21, No. 1. pp. 50-60.
@article{faf886c1a76a417ab938465ba218bbd0,
title = "Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer",
abstract = "Purpose: Women with breast cancer report varying frequencies of cognitive problems during adjuvant systemic therapy. This variability suggests latent subgroups. Therefore, we identified latent subgroups of self-reported cognitive problems among postmenopausal women with and without breast cancer. We explored associations between membership in these subgroups and (a) demographic, clinical, and symptom characteristics and (b) variations in candidate gene polymorphisms. Methods: We evaluated frequency of cognitive problems using the Patient Assessment of Own Functioning Inventory. Growth mixture modeling identified latent subgroups over 18 months of adjuvant systemic therapy and at matched time points for women without cancer (N = 331). We evaluated for differences among subgroups in demographic, clinical, and symptom characteristics and in 41 single nucleotide polymorphisms in 10 candidate genes involved in DNA repair and oxidative stress pathways (n = 199). We modeled associations between genotypes and subgroup membership using multinomial logistic regression. Results: We identified three latent subgroups: more frequent, persistent, and almost never. Receipt of chemotherapy plus anastrozole, depressive symptoms, and baseline neuropathic symptoms increased the odds of belonging to the more frequent subgroup. Anxiety and depressive symptoms increased the odds of belonging to the persistent subgroup. With covariates controlled for, carrying the ERCC5 rs873601 G minor allele increased the odds of reporting more frequent cognitive problems. Conclusions: Chemotherapy plus anastrozole, depressive symptoms, and presence of neuropathic symptoms may predict more frequent cognitive problems during systemic therapy that later resolve. Mood dysregulation before therapy may predict persistent cognitive problems during therapy. ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors.",
keywords = "breast neoplasms, cognition, DNA repair, oxidative stress, self-report",
author = "John Merriman and Sereika, {Susan M.} and Conley, {Yvette P.} and Koleck, {Theresa A.} and Yehui Zhu and Phillips, {Mary L.} and Bertocci, {Michele A.} and Brufsky, {Adam M.} and Bender, {Catherine M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1099800418799964",
language = "English (US)",
volume = "21",
pages = "50--60",
journal = "Biological Research for Nursing",
issn = "1099-8004",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer

AU - Merriman, John

AU - Sereika, Susan M.

AU - Conley, Yvette P.

AU - Koleck, Theresa A.

AU - Zhu, Yehui

AU - Phillips, Mary L.

AU - Bertocci, Michele A.

AU - Brufsky, Adam M.

AU - Bender, Catherine M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Women with breast cancer report varying frequencies of cognitive problems during adjuvant systemic therapy. This variability suggests latent subgroups. Therefore, we identified latent subgroups of self-reported cognitive problems among postmenopausal women with and without breast cancer. We explored associations between membership in these subgroups and (a) demographic, clinical, and symptom characteristics and (b) variations in candidate gene polymorphisms. Methods: We evaluated frequency of cognitive problems using the Patient Assessment of Own Functioning Inventory. Growth mixture modeling identified latent subgroups over 18 months of adjuvant systemic therapy and at matched time points for women without cancer (N = 331). We evaluated for differences among subgroups in demographic, clinical, and symptom characteristics and in 41 single nucleotide polymorphisms in 10 candidate genes involved in DNA repair and oxidative stress pathways (n = 199). We modeled associations between genotypes and subgroup membership using multinomial logistic regression. Results: We identified three latent subgroups: more frequent, persistent, and almost never. Receipt of chemotherapy plus anastrozole, depressive symptoms, and baseline neuropathic symptoms increased the odds of belonging to the more frequent subgroup. Anxiety and depressive symptoms increased the odds of belonging to the persistent subgroup. With covariates controlled for, carrying the ERCC5 rs873601 G minor allele increased the odds of reporting more frequent cognitive problems. Conclusions: Chemotherapy plus anastrozole, depressive symptoms, and presence of neuropathic symptoms may predict more frequent cognitive problems during systemic therapy that later resolve. Mood dysregulation before therapy may predict persistent cognitive problems during therapy. ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors.

AB - Purpose: Women with breast cancer report varying frequencies of cognitive problems during adjuvant systemic therapy. This variability suggests latent subgroups. Therefore, we identified latent subgroups of self-reported cognitive problems among postmenopausal women with and without breast cancer. We explored associations between membership in these subgroups and (a) demographic, clinical, and symptom characteristics and (b) variations in candidate gene polymorphisms. Methods: We evaluated frequency of cognitive problems using the Patient Assessment of Own Functioning Inventory. Growth mixture modeling identified latent subgroups over 18 months of adjuvant systemic therapy and at matched time points for women without cancer (N = 331). We evaluated for differences among subgroups in demographic, clinical, and symptom characteristics and in 41 single nucleotide polymorphisms in 10 candidate genes involved in DNA repair and oxidative stress pathways (n = 199). We modeled associations between genotypes and subgroup membership using multinomial logistic regression. Results: We identified three latent subgroups: more frequent, persistent, and almost never. Receipt of chemotherapy plus anastrozole, depressive symptoms, and baseline neuropathic symptoms increased the odds of belonging to the more frequent subgroup. Anxiety and depressive symptoms increased the odds of belonging to the persistent subgroup. With covariates controlled for, carrying the ERCC5 rs873601 G minor allele increased the odds of reporting more frequent cognitive problems. Conclusions: Chemotherapy plus anastrozole, depressive symptoms, and presence of neuropathic symptoms may predict more frequent cognitive problems during systemic therapy that later resolve. Mood dysregulation before therapy may predict persistent cognitive problems during therapy. ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors.

KW - breast neoplasms

KW - cognition

KW - DNA repair

KW - oxidative stress

KW - self-report

UR - http://www.scopus.com/inward/record.url?scp=85058196724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058196724&partnerID=8YFLogxK

U2 - 10.1177/1099800418799964

DO - 10.1177/1099800418799964

M3 - Article

VL - 21

SP - 50

EP - 60

JO - Biological Research for Nursing

JF - Biological Research for Nursing

SN - 1099-8004

IS - 1

ER -